These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10830789)

  • 1. New clinical trials of angiotensin blockade in cardiovascular disease: foreword.
    Julius S
    Am J Hypertens; 2000 May; 13(5 Pt 2):55S-56S. PubMed ID: 10830789
    [No Abstract]   [Full Text] [Related]  

  • 2. Pulse pressure and dual angiotensin blockade.
    Safar ME
    Am J Hypertens; 2008 Feb; 21(2):133. PubMed ID: 18268484
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.
    Tsouli SG; Liberopoulos EN; Kiortsis DN; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):1-15. PubMed ID: 16703216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibitors in high risk cardiovascular patients: a new hope from the HOPE study.
    Gambhir DS
    Indian Heart J; 2000; 52(2):127-8, 211. PubMed ID: 10893889
    [No Abstract]   [Full Text] [Related]  

  • 5. [The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases].
    Ferrari R; Ambrosio G; Chiariello M
    Ital Heart J; 2005 Nov; 6 Suppl 7():3S-4S. PubMed ID: 16485511
    [No Abstract]   [Full Text] [Related]  

  • 6. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors.
    Menard J; Patchett AA
    Adv Protein Chem; 2001; 56():13-75. PubMed ID: 11329852
    [No Abstract]   [Full Text] [Related]  

  • 8. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice.
    Pitt B
    Heart; 2009 Aug; 95(15):1205-8. PubMed ID: 19401281
    [No Abstract]   [Full Text] [Related]  

  • 9. ACE inhibitors--revisited.
    Sathyamurthy I; Jayanthi K
    J Assoc Physicians India; 2000 Jul; 48(7):715-8. PubMed ID: 11273508
    [No Abstract]   [Full Text] [Related]  

  • 10. The STOP-ACEi Trial - Apt timing for this long awaited randomised controlled trial - Validation of the syndrome of late-onset renal failure from angiotensin blockade (LORFFAB)?
    Onuigbo MA
    Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 27933685
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in preventive cardiology: which drug to use and what to expect in light of the ONTARGET trial.
    Cairns JA
    Pol Arch Med Wewn; 2008 Jun; 118(6):335-8. PubMed ID: 18619187
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?
    Cruden NL; Newby DE
    Am J Cardiovasc Drugs; 2004; 4(6):345-53. PubMed ID: 15554719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I.
    Biollaz J; Burnier M; Turini GA; Brunner DB; Porchet M; Gomez HJ; Jones KH; Ferber F; Abrams WB; Gavras H; Brunner HR
    Clin Pharmacol Ther; 1981 May; 29(5):665-70. PubMed ID: 6260419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Who is fooling us?
    Sleight P; Yusuf S
    Lancet; 2002 Sep; 360(9336):873-4. PubMed ID: 12243941
    [No Abstract]   [Full Text] [Related]  

  • 16. Who is fooling us?
    Mourad JJ; Safar ME; O'Rourke MF
    Lancet; 2002 Jul; 360(9326):89. PubMed ID: 12114069
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials.
    Shunan F; Jiqing Y; Xue D
    J Renin Angiotensin Aldosterone Syst; 2018; 19(4):1470320318803495. PubMed ID: 30296880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin-converting enzyme inhibitors: their application in cardiovascular diseases.
    Cerdeira AS; Brás-Silva C; Leite-Moreira AF
    Rev Port Cardiol; 2008 Mar; 27(3):385-408. PubMed ID: 18551924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction. The cardiovascular continuum in the 21st century: renin-angiotensin system blockade, the cardiovascular continuum in the 21st century.
    Probstfield JL; Weber MA
    Am J Cardiol; 2010 Jan; 105(1 Suppl):1A-2A. PubMed ID: 20102967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.